General
Preferred name
FINAFLOXACIN
Synonyms
BAY-35-3377 ()
Finafloxacin hydrochloride ()
Xtoro ()
AL-60371 ()
Finafloxacin (hydrochloride) ()
P&D ID
PD009392
CAS
209342-40-5
209342-41-6
Tags
available
drug candidate
drug
Approved by
FDA
First approval
2014
Drug Status
investigational
approved
Drug indication
Otitis media
Urinary tract infection
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY -Finafloxacin was shown to be genotoxic and clastogenic in vitro, with and without metabolic activation, and in vivo.; -General toxicity studies in rats have confirmed sperm toxicity following oral and intravenous dosing.; -At 500 mg/kg/day, males were completely infertile, presumably due to low sperm count and sperm immobility.
DESCRIPTION Finafloxacin is a fluoroquinolone antibacterial. (GtoPdb)
Compound Sets
13
Cayman Chemical Bioactives
22410
ChEMBL Approved Drugs
CHEMBL1908370
ChEMBL Drugs
CHEMBL1908370
Drug Repurposing Hub
DrugBank
DB09047
DrugBank Approved Drugs
DB09047
DrugCentral
4920
DrugCentral Approved Drugs
4920
DrugMAP
DMZEONG
DMWYPZF
DrugMAP Approved Drugs
DMZEONG
Guide to Pharmacology
10809
MedChem Express Bioactive Compound Library
HY-13451
ReFrame library
External IDs
37
Properties
(calculated by RDKit )
Molecular Weight
398.14
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
5
Aromatic Ring Count
2
cLogP
1.22
TPSA
107.59
Fraction CSP3
0.45
Chiral centers
2.0
Largest ring
6.0
QED
0.8
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis
Disease Area
infectious disease, pulmonary
MOA
bacterial DNA gyrase inhibitor
Pathway
Anti-infection
Target
antibiotic
Bacterial
Source data